Emerging data present T cell engagers as a promising biologic class capable of inducing 'immune reset' for autoimmune diseases by selectively eliminating autoreactive B cells and plasma cells. This approach goes beyond broad immunosuppression, targeting the root causes to achieve durable remission. Offering scalable administration and patient-friendly dosing, T cell engagers could transform treatment paradigms for diseases currently managed with symptom-focused therapies.